Literature DB >> 18415323

[Pathophysiology of ischemic cardiac pain.].

T Münzel1, E Bassenge.   

Abstract

Cardiac pain is a conscious experience that can be explored only indirectly with experimental approaches. The exact machanisms eliciting cardiac pain still remain obscure. The afferent fibres running in the cardiac sympathetic nerves are regarded as the essential pathway for the transmission of cardiac pain. Atria and ventricle are abundantly supplied with sympathetic sensory innervation. In the spinal cord, impulses transmitted by the sympathetic pathway converge with impulses from somatic thoracic structures onto the same ascending spinothalamic neuron which probably explains the mechanism of referred pain (=projection of pain to another organ). Two hypotheses have been put forward to explain the peripheral mechanism for nociception. The intensity mechanism assumes that pain results from an excessive stimulation of receptive structures normally stimulated at lower levels whereas a specific sensation is considered to result from an excitation of a well defined nociceptive apparatus. Ventricular sympathetic afferent fibres whether myelinated or unmyelinated, always possess some mechanosensitivity and respond to normal chemical and mechanical stimuli, thus displaying properties of polymodal receptors. Afferent vagal fibres may contribute to the mechanisms of cardiac nociception by modulating the threshold and characteristics of pain. Experimental studies identified three main mechanisms, which may be responsible for eliciting cardiac pain during ischemic periods in humans: a) nonphysiological motion of the ischemic left ventricular wall (bulging) and an excitation of mechanical receptors by passive stretching. b) The excitation of free sensory nerve endings by chemicals such as bradykinin, PGE(2), adenosin, histamin or potassium. c) A combination of a and b: algogenic chemicals may sensitize mechanical receptors and therefore lower their threshold for nociception.

Entities:  

Year:  1988        PMID: 18415323     DOI: 10.1007/BF02528611

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  27 in total

1.  ON THE NATURE OF THE SUBSTANCE(S) PRODUCING PAIN IN CONTRACTING SKELETAL MUSCLE: ITS BEARING ON THE PROBLEMS OF ANGINA PECTORIS AND INTERMITTENT CLAUDICATION.

Authors:  L N Katz; E Lindner; H Landt
Journal:  J Clin Invest       Date:  1935-11       Impact factor: 14.808

2.  Excitation of afferent cardiac sympathetic nerve fibers during coronary occlusion.

Authors:  Y Uchida; S Murao
Journal:  Am J Physiol       Date:  1974-05

3.  Search for a cardiac nociceptor: stimulation by bradykinin of sympathetic afferent nerve endings in the heart of the cat.

Authors:  D G Baker; H M Coleridge; J C Coleridge; T Nerdrum
Journal:  J Physiol       Date:  1980-09       Impact factor: 5.182

4.  Different types of slowly conducting afferent units in cat skeletal muscle and tendon.

Authors:  S Mense; H Meyer
Journal:  J Physiol       Date:  1985-06       Impact factor: 5.182

5.  On the origin of cardiac pain. A new hypothesis.

Authors:  S Fisch
Journal:  Arch Intern Med       Date:  1980-06

6.  Afferent sympathetic unmyelinated fibres with left ventricular endings in cats.

Authors:  R Casati; F Lombardi; A Malliani
Journal:  J Physiol       Date:  1979-07       Impact factor: 5.182

7.  Prostaglandins, aspirin-like drugs and analgesia.

Authors:  S H Ferreira
Journal:  Nat New Biol       Date:  1972-12-13

8.  Spinal sympathetic reflexes initiated by coronary receptors.

Authors:  A M Brown; A Malliani
Journal:  J Physiol       Date:  1971-02       Impact factor: 5.182

9.  Effects of intracoronary administration of bradykinin on the impulse activity of afferent sympathetic unmyelinated fibers with left ventricular endings in the cat.

Authors:  F Lombardi; P Della Bella; R Casati; A Malliani
Journal:  Circ Res       Date:  1981-01       Impact factor: 17.367

10.  Prostaglandins and the mechanism of analgesia produced by aspirin-like drugs.

Authors:  S H Ferreira; S Moncada; J R Vane
Journal:  Br J Pharmacol       Date:  1973-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.